ALTERITY THERAPEUTICS LTD (ATHE)

Pharmaceutical Preparations · market cap $71M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alterity Therapeutics (ATHE) is a micro-cap pharmaceutical company with 9 employees and a market cap of approximately $44.5M, focused on its lead asset ATH434, currently in Phase 2 clinical development for Multiple System Atrophy (MSA). The pipeline consists entirely of ATH434 at two dose levels in MSA, making this a single-asset, single-indication story. The next disclosed catalyst is an earnings release on 2026-08-27.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ATH434 dose level 1	Phase 2	Multiple System Atrophy
ATH434	Phase 2	Multiple System Atrophy

Price & technical context

3-month

-33.2%

6-month

+4.9%

12-month

-7.4%

52-wk range

$2.92–$5.89

vs 50-day MA

-15.6%

vs 200-day MA

-9.5%

Realized vol

66.1%

Max drawdown

-55.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ATHE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.